P&G is working with advisers to review up to 100 underperforming brands for potential divestiture.» Read More
CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.
CNBC's Meg Tirrell spoke with Merck CEO Ken Frazier after earnings. Frazier spoke about the competition in hepatitis C, industry consolidation and shared his opinions on the U.S. tax system.
The "Squawk on the Street" news team discusses the quarterly results of Merck and Pfizer.
U.S. stock-index futures rose Tuesday as investors looked to economic reports, earnings and the Fed's mid-week policy decision.
July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, with sales of consumer products and medicines for arthritis and HIV helping to offset the impact of generic competition on other drug sales. Merck, the No. 2 U.S. drugmaker, earned $2.03 billion, or 68 cents per share, in the second quarter.
Stronger earnings for the second quarter and beyond will be the key driver that keeps gas in the bull market gas tank, leading quantitative strategists tell CNBC.
Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.
What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.
Some of the names on the move ahead of the open.
The Fed meets for two days, starting Tuesday, and is widely expected to taper back its monthly bond buying program by another $10 billion to $25 billion - and do little else.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.
July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.
Thirteen stocks in the S&P 500 are targeting 60 percent rises in stock prices...but is it too ambitious? USAToday reports.
LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.
SEOUL, July 16- South Korea has delayed a move to allow certain levels of the animal feed additive zilpaterol in beef to August from mid-July as it finalizes the policy, a food ministry official said on Wednesday.
July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.
July 11- Big Pharma companies are trying to offload low-growth, mature drug portfolios to firms such as Blackstone Group LP and TPG Capital LP which need to figure out how to carve them out, in one of private equity's greatest dealmaking challenges.
Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.